Principal Investigator
Overview
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT04948333
Status
Recruiting
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Mara Westendorp, Research Coordinator
Phone
Email Address
Purpose of Study
The purpose of this study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP), who have previously been treated with at least 2 tyrosine kinase inhibitors. Additionally, this study will investigate the usage of two different dosing regimes of asciminib, 80mg daily and 40mg twice daily.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT04948333
Status
Recruiting
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Mara Westendorp, Research Coordinator
Phone
Email Address
Purpose of Study
The purpose of this study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP), who have previously been treated with at least 2 tyrosine kinase inhibitors. Additionally, this study will investigate the usage of two different dosing regimes of asciminib, 80mg daily and 40mg twice daily.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
